Diagnostic Value of the Biofire®in Community Acquired Pneumonia

Diagnostic Value of the Biofire® Filmarray Pneumonia Panel Compared to Conventional Sputum Culture in Critically il Patients With Pneumonia

This study aimed to determine the impact value of the BioFire FilmArray Pneumonia panel compared to conventional sputum culture in critically ill patients with pneumonia.

the BioFire® FilmArray Pneumonia Panel (BFPP) emerges as a promising candidate for a rapid and multifaceted diagnostic approach.

This study compare the diagnostic accuracy, turnaround time, and impact on antibiotic management decisions of BFPP versus conventional sputum culture in critically ill patients admitted to the ICU with suspected pneumonia.

Inclusion Criteria:

• Patients admitted to the ICU with community acquired pneumonia

Exclusion Criteria:

• Age less than 18 years old.
• End stage malignant patients,
• Patients admitted to the ICU with Acute Lung Injury (ALI).
• Patients admitted to the ICU with Acute Respiratory Distress Syndrome (ARDS).
• Patients with radiological findings suggesting atypical pneumonia.
• Immunocompromised as defined by HIV/AIDS, known immunodeficiency, chronic steroids > 20mg/day Prednisone equivalent, other immunosuppressants.
• Solid organ or bone marrow transplant patients, cystic fibrosis.
• Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.